KISQALI vs ZORTRESS

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 23, 2026·How we rate

Possible drug interaction. KISQALI and ZORTRESS are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	KISQALI	ZORTRESS
Rating	70/100	70/100
Pharmacy pays	—	~$229.16 /30
Type	RX	RX
Active ingredient	RIBOCICLIB SUCCINATE	EVEROLIMUS
Manufacturer	Novartis	Novartis
Dosage forms	Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	Boxed warning
Half-life	—	about 30 hours (mean terminal elimination half-life)
Treats	Breast Neoplasms	—

kisqali zortress

Rating

70/100

Pharmacy pays

—

~$229.16 /30

Type

Active ingredient

RIBOCICLIB SUCCINATE

EVEROLIMUS

Manufacturer

Novartis

Dosage forms

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Boxed warning

Half-life

—

about 30 hours (mean terminal elimination half-life)

Treats

Breast Neoplasms

—

Frequently asked questions

Which is better-rated, Kisqali or Zortress?

Kisqali and Zortress are tied at 3.5 out of 5 by our independent rating.

What is the difference between Kisqali and Zortress?

Kisqali contains Ribociclib Succinate, while Zortress contains Everolimus — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.